SHG:688180 - Shanghai Junshi Biosciences Co Ltd Shanghai Junshi Biosciences Co
Sector: Health Care, Industry: Biotechnology
Add to Watchlist
   
Add Alert 


Yahoo Finance

CNY 58.8    -2.07 (-3.40%)
Show Basic Chart | 3M    6M    1Y    3Y    5Y          

19 Aug 2022


Loading...
Loading...
Loading...

General

CEO: Mr. Jun Xiong

Headquarters: CN

Employees: 2,805

Homepage

Description

Shanghai Junshi, or Junshi, is a China-based biotechnology company that was founded in 2012 and listed on the Hong Kong Stock Exchange and STAR board of the Shanghai Stock Exchange in 2018 and 2020, respectively. It received approval for its first core asset at the end of 2018, a PD-1 inhibitor called Tuoyi or toripalimab. It also successfully created etesevimab, one of the earliest neutralizing antibodies for COVID-19 treatment, which it out-licensed to Eli Lilly and obtained U.S. FDA approval in February 2021. Other near-term drugs in its pipeline include a Humira biosimilar and ongericimab, a PCSK9 inhibitor.

Your Holdings
Dashboard
Portfolio
Options
Other Assets

Tools
Screener
Risk Manager
Other Assets
Watchlist
Alerts
Notes
Wall
Community
Forum
Blogs
Instagram
Facebook
Shared Portfolios
Shared Screeners

Collab
Tiger Brokers x StocksCafe
Saxo Trading x StocksCafe
Kenny REIT Screener

Help
Quickstart Guides
StocksCafe Academy
StocksCafe Youtube Channel

About StocksCafe
Our Story
Send Feedback
Pricing
Market
Singapore
Hong Kong
Tokyo
Kuala Lumpur
United States
London
Shenzhen
Shanghai
Bombay
National (India)
Indexes
Singapore Savings Bonds
CoinGecko
Your Account
Settings
Subscriptions
Referrals
Messages
Profile
IG    FB    YouTube

About · FAQs · StocksCafe © 2022 · Privacy · Terms